This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-09-1083v1 69/21/8310    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Jaetao, J. E. Articles by Larson, R. S. PubMed PubMed Citation Articles by Jaetao, J. E. Articles by Larson, R. S.

Enhanced Leukemia Cell Detection Using a Novel Magnetic Needle and Nanoparticles

¹ Department of Pathology, University of New Mexico and Cancer Research and Treatment Center, Departments of ² Biochemistry and Molecular Biology and ³ Cell Biology and Physiology, University of New Mexico, ⁴ Department of Internal Medicine, Division of Hematology Oncology, University of New Mexico Hospital, and ⁵ Senior Scientific, LLC, Albuquerque, New Mexico; and ⁶ chemicell GmbH, Berlin, Germany

Requests for reprints: Richard S. Larson, University of New Mexico Cancer Research Facility, Room 223, 2325 Camino de Salud, Albuquerque, NM 87131. Phone: 505-272-6950; Fax: 505-272-5186; E-mail: rlarson{at}salud.unm.edu.

Acute leukemia is a hematopoietic malignancy for which the accurate measurement of minimal residual disease is critical to determining prognosis and treatment. Although bone marrow aspiration and light microscopy remain the current standard of care for detecting residual disease, these approaches cannot reliably discriminate less than 5% lymphoblast cells. To improve the detection of leukemia cells in the marrow, we developed a novel apparatus that utilizes antibodies conjugated to superparamagnetic iron oxide nanoparticles (SPION) and directed against the acute leukemia antigen CD34, coupled with a "magnetic needle" biopsy. Leukemia cell lines expressing high or minimal CD34 were incubated with anti-CD34–conjugated SPIONs. Three separate approaches including microscopy, superconducting quantum interference device magnetometry, and in vitro magnetic needle extraction were then used to assess cell sampling. We found that CD34-conjugated nanoparticles preferentially bind high CD34-expressing cell lines. Furthermore, the magnetic needle enabled identification of both cell line and patient leukemia cells diluted into normal blood at concentrations below those normally found in remission marrow samples. Finally, the magnetic needle enhanced the percentage of lymphoblasts detectable by light microscopy by 10-fold in samples of fresh bone marrow aspirate approximating minimal residual disease. These data suggest that bone marrow biopsy using antigen-targeted magnetic nanoparticles and a magnetic needle for the evaluation of minimal residual disease in CD34-positive acute leukemias can significantly enhance sensitivity compared with the current standard of care. [Cancer Res 2009;69(21):8310–6]

Key Words: nanoparticles • bone marrow sampling • leukemia • biotechnology